Alder Biopharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2018; Provides Investment Guidance for the Full Year 2018
For the period, the company reported loss from operations was $150,682,000 against $175,494,000 a year ago. Net loss was $155,420,000 against $174,957,000 a year ago. Net loss applicable to common stockholders was $64,972,000 or $2.77 per basic and diluted share against $74,824,000 or $3.47 per basic and diluted share, a year ago.
The company expected that full year 2018 cash investment will continue to be in the range of approximately $300 million to $320 million.